CD8A and cancer: ICB (e.g., anti-CTLA-4 and anti-PD-L1)-activated CD8+ T cells reduced the expression of two subunits (SLC3A2 and SLC7A11) of the glutamate-cystine antiporter system xc- and limited cystine uptake by cancer cells via IFN-γ release (161).